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Abstract
Background: The objective of this study was to determine the prevalence of nasopharyngeal carriage, serotype
distribution, and penicillin resistance of Streptococcus pneumoniae in children ≤6 years of age in Ghana.
Methods: A cross-sectional study was carried out on a cluster-randomized sample of children ≤6 years of age
attending nurseries and kindergartens in Accra and Tamale, Ghana. Basic data on age, sex and exposure to
antimicrobials in the previous month were collected on all study subjects. Nasopharyngeal swabs were obtained
from participants and all pneumococcal isolates were characterized by serotyping and their penicillin resistance
determined.
Results: The overall prevalence of pneumococcal carriage among the children was 34% in Accra and 31% in
Tamale. The predominant serotypes were 19F, 6B, 23F, and 6A with 23% of the isolates being non-typable in Accra
and 12% in Tamale. Only two isolates (serotypes 19F and 6B) from Tamale had a MIC >2 μg/ml and were classified
as fully penicillin resistant with 45% of the isolates having intermediate resistance.
Conclusions: These findings indicate that the 13-valent pneumococcal conjugate vaccine (PCV-13) recently
introduced in Ghana will cover 48% and 51% of the serotypes identified in Accra and Tamale, respectively. The
23-valent pneumococcal polysaccharide vaccine (PPV-23) will cover 54% of all serotypes detected. The two penicillin
resistant isolates (MIC 32 μg/ml) were serotypes included in both PCV-13 and PPV-23. A nationwide monitoring system
of penicillin susceptibility patterns and pneumococcal serotypes is recommended.
Background
Streptococcus pneumoniae (pneumococcus) is an important
cause of morbidity and mortality among children less than
five years of age, patients with debilitating diseases, the
elderly (≥65 years) and immunocompromised individuals
[1-3]. Globally, around two million children die every
year because of pneumococcal pneumonia and meningitis,
mainly in developing countries [4,5]. In recent years,
there has been an increasing focus on the introduction
of pneumococcal conjugate vaccines (PCV) in resource-
limited countries [6-8]. The introduction of PCV is expected
to reduce the burden of invasive pneumococcal diseases
(IPD) in children as well as the prevalence of drug resistant
S. pneumoniae [7].
Nasopharyngeal carriage of S. pneumoniae always pre-
cedes disease and serves as a reservoir for the transmission
of the pathogen [9]. Although there are more than 90
known pneumococcal serotypes, about 20 serotypes ac-
count for over 75% of the IPD cases [10]. Each serotype
differs in prevalence, age group infected, geographical
distribution, and antimicrobial resistance patterns [11-15].
Local knowledge of circulating serotypes and their anti-
microbial susceptibility profiles is therefore imperative
for the development of effective vaccine strategies and
treatment protocols [7,16]. Several vaccines have been
developed including a 23-valent polysaccharide vaccine
(PPV-23, Pneumovax®, Merck) used to immunize the
elderly and children over two years of age. For children
under two years of age, a 10-valent pneumococcal
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Haemophilus influenzae conjugate vaccine (PCV-10,
GlaxoSmithKline) and a 13-valent pneumococcal con-
jugate vaccine (PCV-13, PrevnarTM, Pfizer Vaccines)
are available.
In Ghana, three studies have assessed the carriage rate
of S. pneumoniae [17-19] but none have reported the
prevalence of both serotypes and penicillin susceptibility
in isolates from healthy children below the age of 6 years.
In this study, we aimed to generate baseline data to inform
vaccine policy and treatment strategies in Ghana. The
objective of the study was, therefore, to determine the
prevalence of pneumococcal carriage, penicillin resist-
ance and the serotype distribution of S. pneumoniae in
children ≤6 years attending nurseries and kindergartens in
two cities in Ghana; Accra in the south and Tamale in the
north.
Methods
Study sites
The cities of Accra and Tamale are located in two geo-
graphical areas in Ghana with distinct climates. Accra
is the capital city of Ghana with a costal climate, and
warm and humid weather conditions. Tamale is the
regional capital of the Northern Region of Ghana. It is
situated close to the Sahara, and has a hotter, drier climate
characterized by dry northeasterly winds (Harmattan)
[19, www.ghanadistricts.com/districts].
Sampling and study design
Random cluster sampling was used to select participants.
Lists of nurseries (children aged <48 months) and kin-
dergartens (children aged 48-72 months) were obtained
from the Education Service of the Accra Metropolitan
Assembly and the Tamale Metropolitan Assembly. A
total of 11 nurseries and kindergartens in Accra and seven
in Tamale were randomly chosen from the lists provided.
All children attending the selected nurseries and kinder-
gartens were eligible to be included in the study. Children
with upper respiratory tract infections at the time of
sample collection and who had been treated with antimi-
crobials in the previous month were excluded. Although
the study sites were mainly situated within the cities, some
of the nurseries and kindergartens were located in slums
and in addition, children may have come from the sur-
rounding villages to attend school in the cities.
Specimen collection
Nasopharyngeal specimens were collected using a WHO
recommended methodology [20]. From March to July
2011, nylon-tipped pediatric sized swabs (Microrheologics,
Brescia, Italy) were used to collect nasopharyngeal speci-
mens. A total of 848 swab samples were obtained from
individual children in Accra (421) and Tamale (427). The
swab specimens were placed in a labeled vial containing
1 ml skim milk-tryptone-glucose-glycerin (STGG) medium
and transported on ice to the laboratory within 3 h
[20]. Depending on the time of the day samples were
either processed within 24 h or stored at −80°C. All S.
pneumoniae isolates were stored in STGG medium
at −80°C until air-lifted on dry ice to Statens Serum
Institut, Copenhagen, Denmark for further characterization.
Characterization of S. pneumoniae
A 10-μl loop subsample of each specimen was cultured
on 5% sheep blood agar plates and incubated overnight
at 37°C in 5% CO2. All alpha-hemolytic organisms were
subjected to Gram staining, optochin susceptibility and
bile solubility tests [20]. Isolates that were optochin sensi-
tive and/or bile soluble were identified as S. pneumoniae.
These isolates were serotyped/grouped by the pneumotest
latex agglutination kit (SSI Diagnostica, Hillerød, Denmark)
and results confirmed by the Quellung reaction using sero-
type specific antisera (SSI Diagnostica) [21]. All specimens
were screened for multiple serotypes. Briefly, the specimens
were cultured in an enrichment broth (Serum broth, SSI
Diagnostica) and then screened using a pneumotest latex
agglutination kit (SSI Diagnostica) [21]. Where multiple
serotypes were observed, they were isolated and serotyped
as described above.
Penicillin resistance was initially determined by agar-
disc diffusion using 1 μg oxacillin discs (Rosco Company,
Denmark). Minimum inhibitory concentrations (MICs)
for all oxacillin resistant isolates were determined using
penicillin G MIC strips (Liofilchem, Italy). Penicillin sus-
ceptibility was defined as susceptible (MIC ≤0.06 μg/ml),
intermediate (>0.06-2 μg/ml) and resistant (>2 μg/ml)
according to the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) guidelines with S.
pneumoniae ATCC 49619 used as a control (EUCAST
Clinical Breakpoint Table v. 2.0, valid from 2012-01-01).
Ethical approval
Ethical approval for the study was obtained from the
University of Ghana Medical School (MS-Et/M.5-P.5.4/
2010-11) and permission to conduct the study was obtained
from the Ministry of Education and Health. Informed con-
sent was provided by the parents of children participating
in the study.
Data analysis
Data were analyzed using Graph Pad Prism version 5 for
descriptive statistical analysis.
Results
Serotype prevalence and distribution
Nasopharyngeal swabs were collected from a total of
848 children ≤6 years of age (52% male). The average
age of the children in both sites was similar (4.1 years in
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Accra and 4.0 years in Tamale). In total 274 children
(32%, 95% CI 29%-36%) were found to carry pneumococci,
with similar rates found in Accra and Tamale (Table 1). Be-
cause the study subjects were from nurseries and kinder-
gartens relatively few children aged 0-11 months (n = 7)
and 12-23 months (n = 73) were included (Table 1).
Carriage of two distinct serotypes occurred in 5% of
children (n = 14), giving a total of 288 serotypes isolated
from the 274 children sampled. Eighteen percent of all
isolates (51/288) were non-typable. The most common
serotypes identified were 19F, 6B, 23F, and 6A (Figure 1
and Table 2). The predominant serotype in Accra was 19F
(16%), followed by 6B, 19C, 23F, 6A, 6C, and 14 (Figure 1
and Table 2). In Tamale, the predominant serotype was
also 19°F (11%), followed by 23F, 6A, 6B, 8, 11A, and 15B
(Figure 1 and Table 2). In both Accra and Tamale the
prevalence of carriage decreased with age (Table 1).
Antimicrobial resistance
In Accra, 66 of S. pneumoniae isolates were oxacillin
resistant while in Tamale 62 of the isolates were resistant.
The oxacillin resistant isolates, plus 13 isolates not tested
for oxacillin were further tested using penicillin G MIC
strips. In total 130/288 isolates (45%) had intermediate
resistance to penicillin and two (from Tamale) were peni-
cillin resistant (MIC 32 μg/ml) (Table 3).
Vaccine coverage
Our serotyping results indicate that PCV-13 covers
approximately half of the serotypes carried by healthy
children ≤6 years of age in our study (48% in Accra and
51% in Tamale), while PPV-23 provides coverage for 55%
of all isolates in our sample (Table 2). In total, PCV-13
covers 55% of the isolates with intermediate penicillin
resistance, compared with PPV-23 which covers 61%. The
coverage rates were similar in both Accra and Tamale.
The two isolates that were fully penicillin resistant were
serotypes 19A and 6B, both of which were covered by
PCV-13 and PPV-23. The majority (80%) of serotypes
seen in children under 24 months of age were covered
by PCV-13 (31/39). A higher proportion of isolates from
children aged 3-6 years were not covered by PCV-13
(Table 2).
Discussion
Recently, the GAVI Alliance (formerly the Global Alli-
ance for Vaccines and Immunization), a partnership of
public and private sector organizations dedicated to
“immunization for all” (www.gavialliance.org), started
the introduction of pneumococcal vaccines in developing
countries, especially in Africa [8], and in May 2012 PCV-13
was introduced in Ghana. Studies on the carriage rates of S.
pneumoniae in healthy subjects should be conducted
before the introduction of conjugate pneumococcal vac-
cination campaigns to provide baseline information on
vaccine coverage and to allow identification of changes to
the serotype distributions resulting from pneumococcal
serotype replacement [8].
Our study provides the first large data set on S.
pneumoniae carriage and serotype distribution in healthy
Table 1 Carriage rate of S. pneumoniae, by age group, in children ≤6 years attending nurseries and kindergartens in
Accra and Tamale, Ghana
Age
group
(months)
Accra Carriage of two distinct serotypesTamale
Total number
of children
Number of children with
carriage of S. pneumoniae
(%) [95% CI]
Number of children
with multiple
serotypes (%)
Total number
of children
Number of children with
carriage of S. pneumoniae
(%) [95% CI]
Number of children
with multiple
serotypes (%)
0-11 4 4 (100) 2 (50) 3 2 (67) 0
(40-100%) (13-98%)
12-23 33 20 (61) 1 (3) 40 16 (40) 0
(42-77%) (25-57%)
24-35 71 30 (42) 3 (4) 66 21 (32) 0
(31-55%) (21-44%)
36-47 135 46 (34) 4 (3) 132 43 (33) 2 (1)
(26-43%) (25-41%)
48-59 158 35 (22) 0 184 48 (26) 2 (1)
(16-29%) (20-33%)
Unknown 20 8 (40) 0 2 1 (50) 0
(19-64%) (1-99%)
Total 421 143 (34) 10 (2) 427 131 (31) 4 (1)
(30-39%) (26-35%)
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Ghanaian children. Carriage prevalence was 31%-34%
in our study compared with the 15% previously reported
in Ghana [18]. This difference might be due to the age
differences between our study subjects (≤6 years of
age) and those of the previous study, which included
children ≤13 years of age [18]. The overall carriage in
our study was relatively low when compared with preva-
lence rates reported in other African countries; 22%-60%
in Kenya [22,23], 62% in Uganda [24], 90% in Gambia [25]
and 35% in Tanzania [26]. This may be due to the low
numbers of children below the age of two years included
in this study (Table 1). As our data on pneumococcal car-
riage were collected before the introduction of PCV-13,
they can serve as a baseline to measure possible future
serotype replacement associated with the introduction of
PCV-13 [8].
Figure 1 Serotype distribution of S. pneumoniae, by gender, in children ≤6 years of age attending nurseries and kindergartens in
Accra and Tamale, Ghana. The serotypes are listed on the X-axis, starting with the NT, and followed by the serotypes covered by PCV-7, PCV-10
and PCV-13. The serotypes covered by PPV-23 are listed consecutively from serotype 4 to serotype 33F (except for serotype 6A, which is not
included in PPV-23).
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Penicillin has been the drug of choice worldwide for the
treatment of pneumococcal infections. However, penicillin
resistant strains have emerged, resulting in a shift to the
use of other drugs, e.g. cefotaxime, chloramphenicol and
erythromycin [18]. In an earlier carriage study from the
Ashanti region of Ghana, 49% of children were found
to carry S. pneumoniae and 39% of isolates showed inter-
mediate penicillin resistance [17]. Holliman et al. [27]
described the history of S. pneumoniae penicillin resistance
in Ghana and found that overall around 12% of isolates
Table 2 Combined distribution of S. pneumoniae serotypes and vaccine coverage in children ≤6 years attending
nurseries and kindergartens in Accra and Tamale, Ghana
Age of children (Accra/Tamale), months Total number Accra/Tamale Serotype included in vaccine
Serotype 0-11 12-23 24-35 36-47 48-59 Unknown All age groups
NT 0/1 0/2 9/0 14/8 9/5 3/0 35/16
4 0/0 1/0 0/0 0/2 0/0 0/0 1/2 PCV-10, PCV-13, PPV-23
6B 1/0 0/3 3/0 2/2 8/4 1/0 15/9 PCV-10, PCV-13, PPV-23
9V 0/0 0/0 1/1 1/0 0/1 0/0 2/2 PCV-10, PCV-13, PPV-23
14 0/0 3/0 2/2 1/0 1/1 1/0 8/2 PCV-10, PCV-13, PPV-23
18C 0/0 0/0 0/0 0/2 0/2 0/0 0/4 PCV-10, PCV-13, PPV-23
19F 1/1 12/5 4/4 3/3 2/1 1/0 23/14 PCV-10, PCV-13, PPV-23
23F 2/0 1/2 0/0 5/3 0/8 0/0 8/13 PCV-10, PCV-13, PPV-23
1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 PCV-10, PCV-13, PPV-23
5 0/0 0/0 0/0 0/0 0/0 0/0 0/0 PCV-10, PCV-13, PPV-23
7F 0/0 0/0 0/0 0/0 1/0 0/0 1/0 PCV-10, PCV-13, PPV-23
3 0/0 1/0 1/2 3/0 1/2 0/0 6/4 PCV-13, PPV-23
6A 1/0 0/1 3/5 4/1 0/6 0/0 8/13 PCV-13
19A 0/0 0/0 1/1 0/2 1/2 0/1 2/6 PCV-13, PPV-23
2 0/0 0/0 0/0 0/0 0/0 0/0 0/0 PPV-23
8 0/0 1/1 1/0 0/4 0/0 0/0 2/5 PPV-23
9N 0/0 0/0 0/0 0/0 2/1 0/0 2/1 PPV-23
10A 0/0 0/0 0/0 0/0 0/0 0/0 0/0 PPV-23
11A 0/0 0/0 0/2 3/3 1/1 0/0 4/6 PPV-23
12F 0/0 0/0 0/0 0/1 0/2 0/0 0/3 PPV-23
15B 0/0 0/0 0/2 2/2 0/1 0/0 2/5 PPV-23
17F 0/0 0/0 0/0 1/0 0/0 0/0 1/0 PPV-23
20 0/0 0/0 0/0 0/0 1/1 0/0 1/1 PPV-23
22F 0/0 0/0 0/0 0/0 0/0 0/0 0/0 PPV-23
33F 0/0 0/0 0/0 0/2 0/0 0/0 0/2 PPV-23
Other 1/0 2/2 8/3 11/10 8/12 2/0 32/27 Non-vaccine serotypes
Table 3 Distribution of S. pneumoniae isolates with intermediate and full penicillin resistance by vaccine coverage
Vaccine coverage Number of isolates Penicillin Penicillin
(MIC 0.06-2) (MIC > 2)
Accra Tamale Accra Tamale Accra Tamale
(N = 153) (N = 135) (N = 67) (N = 63) (N = 0) (N = 2)
Non-typable 35 16 10 7 0 0
PCV-7 57 46 30 19 0 1
PCV-10 58 46 30 19 0 1
PCV-13 74 69 40 32 0 2
PPV-23 78 79 40 39 0 2
NON-PCV 79 66 27 31 0 0
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tested were intermediate resistant with the exception of a
study in 1996 that reported 31% of isolates to be resistant
[28]. However, this high rate of resistance was suspected to
be due to the methodology used in the specific study
[27,28]. In a recent study conducted in the Ashanti region
from 2008 to 2010, 99% of 91 invasive S. pneumoniae
isolates were penicillin sensitive [29]. In our study, two
isolates were found to be fully penicillin resistant and
45% (n = 130) showed intermediate penicillin resistance.
These data suggest that intermediate resistance to penicil-
lin has increased among S. pneumoniae in Ghana during
the last 5-10 years and that the prevalence of penicillin
resistance is in line with the situation in other African
countries. Despite a possible increase in intermediate
penicillin resistance, and depending on the site of infection,
penicillin can still be used for the treatment of pneumo-
coccal infections in Ghana.
The S. pneumoniae serotypes found show that PPV-23
covers 55% of serotypes while PCV-10 and PCV-13 cover
40% and 50% of serotypes, respectively. As PCV-13 is
currently used nationwide in Ghana to vaccinate chil-
dren ≤5 years with a vaccination schedule at 6, 10 and
14 weeks, there might be a high risk of replacement
with serotypes not covered by PCV-13. In addition, a high
proportion of non-vaccine serotypes exhibited intermedi-
ate resistance to penicillin. It is therefore imperative
that nasopharyngeal carriage and penicillin resistance
of S. pneumoniae be monitored regularly in children [8].
Prior to our study, limited data were available on serotype
distribution among S. pneumoniae in Ghana [18,19]. Thus,
contrary to recommendations [7,8] recent surveillance data
on prevalent serotypes were not available in Ghana when
PCV-13 was introduced in May 2012. Our finding that
only 50% of the serotypes found are included in PCV-13
highlights the importance of conducting such carriage
studies before the introduction of any vaccine.
In this study we focused on children from nurseries and
kindergarten, and as a result, very few children <11 months
of age were included. This is a limitation of the study, as
other studies in Africa have shown a very high carriage
rates in this age group [30]. We chose to study children
attending nurseries and kindergartens as the length of
time and close physical proximity to other children in
such locations constitutes an optimal environment for
horizontal spread of pneumococci [31]. These sites act like
reservoirs of different serotypes, which can then easily
spread to the surrounding community. It is therefore of
interest to see which non-vaccine serotypes might take
over after vaccination [32]. Although we only recruited
children from two cities in Ghana, we are of the opinion
that the data on carriage rates are representative of other
regions of Ghana as we did not observe large differences
between the carriage rates of the two sites, Accra and
Tamale, even though they are geographically apart and
have different climates. In addition, we did not observe any
marked differences in serotype distribution between the
two study sites (Figure 1, Tables 1 and 2).
Conclusions
The increase in intermediate penicillin resistance in S.
pneumoniae in Ghana is of some concern and should be
monitored carefully. The current study shows that PCV-13,
introduced in Ghana in 2012, covers only 50% of the
prevalent serotypes found in healthy child carriers and
that the risk for serotype replacement is high. Thus, regular
monitoring of pneumococcal carriage is essential to identify
newly dominant serotypes for future vaccine formulations
and to determine prevalence of antimicrobial resist-
ance. Our study provides the most recent baseline data
for pneumococcal serotypes and penicillin resistance in
Ghanaian children.
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